Primary liver cancer has been called the “king of cancers” mainly because only about 1/5 of patients have the chance of surgical resection when primary liver cancer is detected, and the remaining 4/5 of patients often have only 3-6 months of survival, so it has been called the “king of cancers”. Therefore, it is called “the king of cancer”. Interventional therapy can effectively control the development of lesions through comprehensive treatment technologies such as vascular embolization technology, local ablation technology and molecular targeted drug therapy, while portal vein stenting technology and particle implantation technology can solve the problem of portal vein embolism, and portal vein shunt via jugular vein can solve the symptoms of portal hypertension (such as vomiting blood, ascites and abdominal distension) caused by liver cancer and cirrhosis. With the advent of interventional techniques, the remaining 4/5 patients have significantly prolonged their survival, thus losing the title of “king of cancers”. Prevention of primary liver cancer is important, and patients with early detection of liver cancer have a high survival rate after surgery, but once they reach the middle and late stages, the effectiveness of treatment is greatly reduced. For Chinese patients, the majority of them are accompanied by hepatitis, especially hepatitis B and C. Therefore, patients with hepatitis B should undergo hepatitis B virus DNA testing, and if the count is >103, they should adhere to long-term antiviral therapy. It is recommended that liver ultrasound examination be performed every 3 months or so, which is both convenient and affordable, with a view to early detection and treatment, and patients should also quit smoking and drinking spicy and stimulating foods to reduce the burden on the liver, and timely liver-protective treatment should be given when liver function indicators are abnormal. When hepatocellular carcinoma is found, if the opportunity of surgical treatment is lost, the current evidence-based medical evidence shows that liver interventional therapy, that is, hepatic artery infusion chemoembolization, should be preferred, and according to the interventional treatment, local ablation therapy should be combined, which involves the interventional treatment of “infusion”, “blocking” and “elimination”. “According to the patient’s disease stage, the combination of molecular targeted drugs for systemic treatment should be considered to achieve the perfect combination of local and systemic treatment. When complications of liver cancer occur, such as portal hypertension (such as vomiting blood, ascites and abdominal distension) caused by liver cancer and cirrhosis, the cause of portal hypertension is because of cirrhosis or portal vein cancer embolism, which leads to poor blood flow from intestine to liver, and intestinal stasis will cause abdominal distension and ascites, and blood shunts to esophageal vein at the bottom of stomach, which makes the blood vessels of stomach wall varicose and bleed under excessive pressure, thus causing vomiting blood, just like the downstream of river If the river is blocked, it will cause the river to break its banks and flood. Interventional treatment can lower the portal vein pressure and relieve the symptoms of portal hypertension by opening a pathway between the portal vein and the hepatic vein in the liver, which is equivalent to creating an unblocked river and introducing the blocked blood into the inferior vena cava system back to the heart. The presence of cancer thrombus in the portal vein not only increases the pressure in the portal vein, but also seriously affects the survival time of the patient. Interventional therapy, through the “through” technique, places a metal stent and radioactive particle strips in the portal vein, the stent opens the blood flow in the portal vein, and the particles inhibit the growth of cancer thrombus through continuous close irradiation, thus prolonging the survival time of the patient. Various techniques of interventional therapy have effectively prolonged the survival of patients with mid- to late-stage liver cancer, bringing a new light of life to liver cancer patients.